Bain & Company and Bessemer Venture Partners have published their 2026 Healthcare AI ROI Scorecard, based on a survey of 226 healthcare C-suite executives covering 65 use cases across health systems, commercial payers and biopharma companies.
The findings indicate that AI investments are generating returns faster than many organizations initially expected. Enterprise buyers typically modeled a 24-month payback period, while deployed solutions have generated material returns in approximately 12 months on average. Across use cases, average realized ROI reached 3.5x, with 54% producing material returns within their first year and around 40% exceeding initial financial expectations.
Operational and administrative workflows have delivered the highest returns. Provider revenue cycle management led at 4.0x ROI, with 67% of solutions operating as semi- or fully autonomous agents. Payer claims operations and pharmaceutical preclinical discovery each generated 3.4x ROI, while payer provider network management reached 3.3x and member engagement 3.2x.
Provider patient-access applications generated 3.1x ROI, while clinical workflows delivered 2.9x. Clinical AI remains less autonomous, with only 4% of deployed solutions operating semi- or fully autonomously. Pharmaceutical commercial applications generated 2.6x ROI, and clinical development produced 2.3x, reflecting longer trial timelines.
The report also identified changes in how healthcare organizations procure and manage AI. Forty-two percent of buyers have completed or are pursuing vendor consolidation, while adoption has shifted toward healthcare-focused vendors and established healthcare IT companies. Meanwhile, 61% of organizations reported that half or fewer of their internally developed AI tools remain maintained and active.
Workforce effects are becoming more visible. Half of surveyed organizations have reduced headcount because of AI or expect to do so within six months, with affected functions facing average reductions of 8% to 13%. Revenue cycle and billing account for most reported provider reductions, while claims operations lead among payers.
Clinical adoption remains constrained by trust, liability, regulatory uncertainty and reimbursement. Only 46% of clinicians trust AI-generated clinical decision tools, while 77% override AI recommendations more than half the time, highlighting the gap between administrative automation and autonomous clinical use.
Click here for the original news story.
